The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price gain of 21.24% this year. Over the last six months, there has been a stronger performance of -1.60%. The price of HALO leaped by -13.44% during the last 30 days period. For the last 5-days stocks have slided -24.83%.
The market performance of Halozyme Therapeutics Inc’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $65.53 on 08/29/24, while the lowest value for the same duration was $33.15 on 02/05/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of HALO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Halozyme Therapeutics Inc’s current trading price is -31.62% away from its 52-week high, while its distance from the 52-week low is 35.17%. The stock’s price range during this period has varied between$33.15 and $65.53. The Halozyme Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 3.77 million for the day, a figure considerably higher than their average daily volume of 1.54 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Halozyme Therapeutics Inc (HALO) has experienced a quarterly decline of -27.92% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.70B and boasts a workforce of 373 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 56.10, with a change in price of -7.55. Similarly, Halozyme Therapeutics Inc recorded 1,474,611 in trading volume during the last 100 days, posting a change of -14.42%.
HALO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HALO stands at 3.32. Similarly, the long-term debt-to-equity ratio is also 3.32.
HALO Stock Stochastic Average
Halozyme Therapeutics Inc’s raw stochastic average for the past 50 days is presently 13.03%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 13.92%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 5.62% and 18.95%, respectively.
